David Doherty Sells 14,574 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) CFO David Doherty sold 14,574 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $13.84, for a total transaction of $201,704.16. Following the completion of the sale, the chief financial officer owned 88,803 shares of the company’s stock, valued at approximately $1,229,033.52. The trade was a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Surgery Partners Price Performance

Shares of Surgery Partners stock traded down $0.06 on Monday, hitting $13.30. 1,453,571 shares of the company were exchanged, compared to its average volume of 1,733,344. The company has a quick ratio of 1.71, a current ratio of 1.87 and a debt-to-equity ratio of 1.15. The company has a 50-day moving average price of $15.16 and a 200 day moving average price of $18.00. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -21.45 and a beta of 1.95. Surgery Partners, Inc. has a 1-year low of $12.25 and a 1-year high of $24.60.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The company had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. During the same period in the prior year, the business posted $0.44 EPS. Surgery Partners’s revenue for the quarter was up 2.4% compared to the same quarter last year. As a group, sell-side analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Surgery Partners announced that its Board of Directors has initiated a share repurchase program on Thursday, February 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 9.7% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on SGRY shares. Royal Bank Of Canada dropped their price objective on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a research note on Monday, December 29th. Benchmark reiterated a “buy” rating on shares of Surgery Partners in a report on Tuesday, March 3rd. Mizuho dropped their price target on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Barclays cut their price target on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a report on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.45.

Trending Headlines about Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

Institutional Trading of Surgery Partners

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp lifted its position in Surgery Partners by 313.1% in the third quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock valued at $27,000 after buying an additional 930 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Surgery Partners by 45,640.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock valued at $49,000 after acquiring an additional 2,282 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Surgery Partners by 128.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company’s stock valued at $58,000 after acquiring an additional 1,519 shares during the period. Aquatic Capital Management LLC purchased a new stake in shares of Surgery Partners in the 3rd quarter valued at approximately $121,000. Finally, State of Alaska Department of Revenue purchased a new position in shares of Surgery Partners during the 3rd quarter worth approximately $151,000.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.